亨廷頓舞蹈症：新療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 德國亨廷頓舞蹈症市場預計將從約 4,200萬美元成長到 1.3億美元，這表明市場將大幅擴張。
• 市場成長受以下因素支撐：
• 擴大症狀治療和多學科疾病管理
• 基因靜默與疾病修正治療的發展進展
• 人們對診斷的認知不斷提高，以及基因檢測的普及，都促進了患者群體的擴大。
• 未來市場成長將很大程度上取決於針對突變亨廷頓蛋白路徑的下一代疾病修飾療法的商業化成功。

亨廷頓氏舞蹈症的新治療方法及對TPP的深入研究

Thelansis 發布的《亨廷頓舞蹈症：新型療法、未滿足的需求和目標產品概況（TPP）洞察報告，2026》對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況（TPP）、試驗設計和關鍵意見領袖（KOL）的見解。

亨丁頓舞蹈症概述

亨廷頓氏舞蹈症（HD）是一種罕見的、進行性的體染色體顯性遺傳神經退化性疾病，由HTT基因中CAG三核苷酸重複序列的擴增引起，導致產生有毒的突變型亨廷頓蛋白（mHTT）。此病以神經元進行性性退化為特徵，尤其是在紋狀體和大腦皮層，最終導致運動障礙、認知功能下降和精神症狀加重。此病常有遺傳領先，發病年齡往往越早，病情越嚴重。

臨床上，亨丁頓舞蹈症主要表現為三種症狀：運動、認知和精神症狀。早期通常表現為過度活躍的運動，例如舞蹈症；隨著晚期，逐漸發展為肌張力增高、肌張力不全症、協調障礙和嚴重的機能衰退。認知障礙逐漸發展為皮質下失智症，並伴隨憂鬱症、冷漠、焦慮、易怒和衝動行為等精神症狀，這些症狀嚴重影響患者的生活品質，加重看護者的負擔。

目前，尚無核准的根治性或疾病修飾療法治療方法阻止或逆轉疾病進展，治療仍以症狀支持為主。 VMAT2抑制劑，包括Tetrabenazine和Deutetrabenazine，常用於治療舞蹈症，而抗憂鬱症、抗精神病藥物和多學科支持治療則用於治療精神症狀。隨著基因靜默療法、RNA標靶療法和緩解疾病策略日益受到關注，這些療法有望徹底改變亨丁頓舞蹈症未來的治療模式。

主要亮點

• 在美國，亨廷頓舞蹈症的診斷數量預計將從約 39,486 例增加到 42,458 例，反映出確診患者數量的逐漸增加。
• HD仍然是神經退化性疾病，由於沒有核准的疾病修正治療，因此存在很大的未滿足需求。
• 運動障礙、認知能力下降和精神併發症持續顯著加重疾病負擔和對照護的依賴。
• 隨著新的基因標靶治療和基於 RNA 的治療方法的出現，人們對血液透析（HD）治療的研究和開發的興趣顯著成長。
• 人們意識的提高和基因檢測技術的進步，使得患者的診斷和識別能夠更早進行。

從對醫生和關鍵意見領袖的調查中獲得的見解：

• 透過對關鍵意見領袖（KOL）的訪談，獲得了更多見解，進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 主要企業
• 主要作用機制
• 發布日期等的預測
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機會
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵KOL洞察對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

主要企業

• SOM Innovation Biotech SA
• Neurocrine Biosciences
• Skyhawk Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Hoffmann-La Roche
• Alnylam Pharmaceuticals
• Supernus Pharmaceuticals, Inc.
• UniQure Biopharma BV
• Novartis Pharmaceuticals
• Prilenia
• ExoRNA Bioscience
• Medibiofarma SL
• Wave Life Sciences Ltd.
• PTC Therapeutics

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法 - 概述和KOL洞察

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章 一級市場調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章 未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與償付環境

第7章 附錄

Huntington Disease Emerging Therapy and TPP Insights

Thelansis's "Huntington Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Huntington's Disease Overview

Huntington's disease (HD) is a rare, progressive, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, resulting in the production of toxic mutant huntingtin (mHTT) protein. The disease is characterized by progressive degeneration of neurons, particularly within the striatum and cerebral cortex, leading to worsening motor dysfunction, cognitive decline, and psychiatric disturbances. Genetic anticipation is commonly observed, with successive generations often experiencing earlier disease onset and increased severity.

Clinically, HD presents with a triad of motor, cognitive, and psychiatric symptoms. Early disease is typically associated with hyperkinetic movements such as chorea, while advanced stages progress toward rigidity, dystonia, impaired coordination, and severe functional decline. Cognitive impairment gradually evolves into subcortical dementia, accompanied by psychiatric manifestations including depression, apathy, anxiety, irritability, and impulsive behavior, significantly impacting patient quality of life and caregiver burden.

Currently, no curative or disease-modifying therapies are approved to halt or reverse disease progression, and management remains primarily symptomatic and supportive. VMAT2 inhibitors, including tetrabenazine and deutetrabenazine, are commonly used to manage chorea, while psychiatric symptoms are addressed through antidepressants, antipsychotics, and multidisciplinary supportive care. Increasing research focus on gene-silencing therapies, RNA-targeted approaches, and disease-modifying strategies is expected to reshape the future treatment landscape for HD.

Key Highlights

• In the USA, diagnosed Huntington's disease cases are projected to increase from approximately 39,486 to 42,458, reflecting a gradually increasing diagnosed patient population.
• HD remains a high unmet need neurodegenerative disorder due to the absence of approved disease-modifying therapies.
• Motor dysfunction, cognitive decline, and psychiatric complications continue to contribute substantially to disease burden and caregiver dependency.
• Emerging gene-targeting and RNA-based therapies are driving significant research and clinical development interest in HD treatment.
• Increasing awareness and improved genetic testing are supporting earlier diagnosis and patient identification.

Market Overview

• The Germany Huntington's disease market is projected to grow from approximately $42 MN to $130 MN, reflecting significant market expansion.
• Market growth is supported by:
• Increasing adoption of symptomatic therapies and multidisciplinary disease management
• Advancing development of gene-silencing and disease-modifying therapeutic approaches
• Rising diagnostic awareness and improved access to genetic testing are contributing to patient pool expansion.
• Future market growth will largely depend on successful commercialization of next-generation disease-modifying therapies targeting mutant huntingtin protein pathways.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• SOM Innovation Biotech SA
• Neurocrine Biosciences
• Skyhawk Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Hoffmann-La Roche
• Alnylam Pharmaceuticals
• Supernus Pharmaceuticals, Inc.
• UniQure Biopharma B.V.
• Novartis Pharmaceuticals
• Prilenia
• ExoRNA Bioscience
• Medibiofarma S.L.
• Wave Life Sciences Ltd.
• PTC Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)